EFFECTIVE TREATMENT METHODS FOR BREAST CANCER IN ELDERLY WOMEN
Keywords:
breast cancer, elderly women, old age, molecular subtype, adjuvant treatment, endocrine therapy, chemotherapy, radiotherapy, surgery.Abstract
Breast cancer represents a major health concern among women and its prevalence tends to rise with increasing age. As global life expectancy continues to increase, the number of older women diagnosed with breast cancer and requiring appropriate therapeutic management is also growing. Advanced age is considered an important risk factor for the development of breast cancer, with a considerable proportion of cases occurring in women aged 60 years and above. Treating breast cancer in elderly patients presents particular clinical challenges due to age-associated physiological alterations, the presence of multiple comorbidities, reduced functional capacity, and age-related variations in tumor characteristics. Consequently, therapeutic strategies should be carefully tailored to each patient, taking into account the tumor’s molecular subtype, stage of disease, functional and general health status, estimated life expectancy, existing comorbidities, and the patient’s individual treatment preferences.
Objective. The aim of this review was to analyze current approaches to the treatment of breast cancer in elderly women and to evaluate the role of surgical treatment, adjuvant systemic therapy, endocrine therapy, chemotherapy, and radiotherapy according to tumor subtype and patient characteristics.
Materials and Methods. The article is based on an analysis of scientific publications concerning the treatment of breast cancer in women aged 60 years and older. Particular attention was paid to molecular subtypes of breast cancer, surgical treatment, endocrine therapy, chemotherapy, radiotherapy, and the influence of concomitant diseases and functional status on treatment selection.
Results. The analysis demonstrated that breast cancer in elderly women is biologically heterogeneous and requires an individualized therapeutic approach. Hormone receptor-positive and HER2-negative tumors, particularly luminal A tumors, are frequently encountered in older patients and may respond favorably to endocrine therapy. Tamoxifen and other endocrine approaches may represent important components of adjuvant treatment. In selected patients, omission or modification of radiotherapy may be considered depending on tumor characteristics, endocrine treatment, life expectancy, and recurrence risk. Surgical treatment remains an important component of management, although the extent of surgery and axillary lymph-node intervention should be individualized. Chemotherapy requires careful consideration because age-related physiological changes and comorbidities may increase the risk of treatment-related toxicity.
Conclusion. Treatment of breast cancer in elderly women should be based not on chronological age alone but on tumor biology, disease stage, functional status, comorbidities, life expectancy, and patient preferences. Surgery remains an important treatment modality, while endocrine therapy plays a particularly important role in hormone receptor-positive disease. Radiotherapy and chemotherapy should be considered according to individual risk-benefit assessment. Further development of standardized geriatric and oncological assessment approaches may improve treatment selection in this patient population.
References
1.Evaluation of Postoperative Outcomes in Elderly Women With Breast Cancer. Scientific Journal of Applied and Medical Sciences. 2023;2(3):39–42.
2.Mamedov US, Temirova DV. Otsenka posleoperatsionnykh iskhodov u pozhilykh zhenshchin s rakom molochnoy zhelezy. Science and Technology in Modern World. 2023;2(9):73–74.
3.Makhmudova GF, Temirova DV, Barotova ShB. Uterus neck dangerous tumors to age special features. Academic Research in Educational Sciences. 2021;2(5):186–196.
4.Mamedov US, Temirova DV, Mahmudova GF. Sut bezi saratoni bilan keksa yoshdagi ayollarda davolash usullari. Journal of Healthcare and Life-Science Research. 2023;2(4).
5.Temirova DV. Sut bezi saratoniga chalingan keksa yoshdagi bemorlarda operatsiyadan keyingi davolash natijalarini baholash. Amaliy va Tibbiyot Fanlari Ilmiy Jurnali. 2024;3(3):5–8.
6.Temirova DV. Milk diaper to cancer played old age in patients from surgery next treatment the results evaluation. Research Journal of Trauma and Disability Studies. 2024;3(3):198–201.
7.World Health Organization. Ageing and health. WHO publications.
8.National and international clinical recommendations for the diagnosis and treatment of breast cancer in elderly patients.
9.AbeO, AbeR, EnomotoK, etal. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687–717
10.Albain K, Anderson S, Arriagada R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379(9814):432–44
11.Alberini J.L., Meunier В., Denzler B. et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography // Breast Cancer Res. Treat - 2000. - Vol. 61. -P. 21-32.
12.Allen В., Campbell 1., Desai S et al Pilot study companng the accuracy of lymphoscintigraphy sentinel lymph node localisation with axillary node dissection in women with operable breast cancer // N. Z. Med. J -2001. -Vol 114.-P 233-236
13.Anderson BO et al. 2008 . Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer, 113, 2221–43.
14.Anderson W.F., Pfeiffer R.M., Dores G.M.,Sherman M.E. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10): 1899−905
15.Anderson W.F., Pfeiffer R.M., Dores G.M.,Sherman M.E. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10): 1899−905
16.Antoniou A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies // Am. J. Hum. Genet. – 2003. – Vol.72. – P.1117-1130
17.Arriagada R., Le M. G., Guinebretiere J. M. et al. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients // Ann. Oncol-2003-N 11-P. 1617-1622
18.Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28(23):3784–96
19.Balducci L, Beghe C. Cancer and age in the USA. CritRevOncolHematol 2001;37: 137–45
20.BalducciL. Geriatriconcology. CritRevOncolHematol 2003;46:211–20
21.Campone M, Peron J, Freyer G, et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol 2011;80(3):466–73
22.Cancer, International Agency for Research on. Cancer Mundial IARC, págs. http://www-dep.iarc.fr.
